Frances R. Levin

Frances Rudnick Levin, MD is the Kennedy-Leavy Professor of Psychiatry at Columbia University and the Chief of the Division on Substance Use Disorders; NYSPI/Columbia University. For over twenty years, she served as the Director of the Addiction Psychiatry Fellowship Program at New York Presbyterian Hospital and for the past fifteen years, she has been the PI of a T32 NIDA funded Substance Abuse Research Fellowship. She is Medical Director of the Providers’ Clinical Support System – Medication Assisted Treatments (PCSS), a SAMHSA-supported national training and mentoring initiative focused on addressing the opioid use disorder crisis. Also, she is the Medical Director  of  a  SAMHSA-supported  State  Targeted  Response  technical  assistance grant to states that received funding to address the national opioid epidemic.

She is the principal investigator on several federally funded grants, including a U54 Medications Development grant evaluating novel treatments for opiate and cannabis use disorders, and a K24 Mid-Career Investigator Award. She also serves as a site PI for several multi-site pharmacologic trials targeting novel interventions for cannabis and opioid use disorders.

She is an internationally known expert in the diagnosis and treatment of adult ADHD among those with comorbid substance use disorders. Her work has demonstrated that ADHD can be reliably diagnosed and both ADHD and cocaine use disorder can be effectively treated simultaneously. Also, she conducted some of the first studies investigating pharmacologic interventions for adults with cannabis use disorders and is a recognized national leader in the assessment of treatment outcome and novel interventions for adults with cannabis use disorders.

Her current research interests include combining computerized behavioral interventions with pharmacotherapies using a smart design for stimulant use disorders, developing novel induction methods onto medications for opioid use disorders among those using highly potent synthetic opioids, and assessing treatments for adults with cannabis use disorders and attention- deficit hyperactivity disorder. She has served on several advisory panels and ad-hoc federal grant review groups and was as a member of the NIDA – Initial Review Group: Training and Career Development Subcommittee for 8 years and served as a member to the NIDA Interventions to Prevent and Treat Addiction (IPTA). She currently serves as a Board member for the Committee on Problems for Drug Dependence, is on the Medical Advisory Panel for the Office of Addiction Services and Supports (OASAS), is past President of the American Academy of Addiction Psychiatry and past Chair of the APA Council on Addiction Psychiatry.